

OFFICE OF THE SECRETARY OF STATE

SHEMIA FAGAN  
SECRETARY OF STATE

CHERYL MYERS  
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION

STEPHANIE CLARK  
DIRECTOR

800 SUMMER STREET NE  
SALEM, OR 97310  
503-373-0701

**NOTICE OF PROPOSED RULEMAKING**  
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 855  
BOARD OF PHARMACY

**FILED**

02/23/2022 2:59 PM  
ARCHIVES DIVISION  
SECRETARY OF STATE

FILING CAPTION: Amends "Supervision by a Pharmacist"; Moves some definitions in Division 041/139 to Division 006

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 03/29/2022 4:30 PM

*The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.*

CONTACT: Rachel Melvin  
971-673-0001

800 NE Oregon St., Suite 150  
Portland, OR 97232

pharmacy.rulemaking@bop.oregon.gov

Filed By:  
Rachel Melvin  
Rules Coordinator

HEARING(S)

*Auxiliary aids for persons with disabilities are available upon advance request. Notify the contact listed above.*

DATE: 03/29/2022

TIME: 9:30 AM

OFFICER: Rachel Melvin

ADDRESS: Oregon Board of Pharmacy

800 NE Oregon St., Suite 150

Portland, OR 97232

SPECIAL INSTRUCTIONS:

This hearing meeting will be held virtually via Microsoft Teams.

If you wish to present oral testimony during this hearing, sign up on our website at [www.oregon.gov/pharmacy/pages/rulemaking-information](http://www.oregon.gov/pharmacy/pages/rulemaking-information) or email your contact information to [pharmacy.rulemaking@bop.oregon.gov](mailto:pharmacy.rulemaking@bop.oregon.gov) to receive the link to join the virtual meeting. Please indicate which rule(s) you would like to comment on.

Alternatively, you may dial (503) 446-4951 Phone Conference ID: 414 724 81# for audio only.

You may file written comments before 4:30PM on March 29, 2022 by emailing your comments to [pharmacy.rulemaking@bop.oregon.gov](mailto:pharmacy.rulemaking@bop.oregon.gov)

NEED FOR THE RULE(S)

The proposed language amends "supervision by a pharmacist" to include an exception for telework as authorized under OAR 855-041-3200 through OAR 855-041-3250.

Moves definitions for "biological product", "biosimilar", "interchangeable", "reference biological product" and "repackage" from Divisions 041/139 to Division 006. Moves definitions for "still image capture", "store and forward" and "telepharmacy system" to Division 006. Adds definition for "temperature excursion".

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

None available.

---

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

Amending the definition of "supervision by a pharmacist" will impact a licensee's ability to work remotely. The ability to work remotely allows employers to hire licensees that do not live in their geographical region; thus, allowing employers to seek out more diverse employees; thus, it is anticipated that these rules will have some potential impact on racial equity. Adoption of this definition may positively impact all licensees throughout Oregon by allowing some work to be performed outside of a traditional brick and mortar pharmacy location, which may also increase employee performance and assist with work life balance. Reorganizing proposed rules may provide clarity, transparency and promote patient safety, no effects on racial equity are anticipated. Ensuring registrants and licensees are able to easily locate definitions will positively impact all Oregonians in all communities.

---

FISCAL AND ECONOMIC IMPACT:

None anticipated.

---

COST OF COMPLIANCE:

*(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).*

None anticipated.

---

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses were not involved with the development of the proposed rule amendment.

---

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

A RAC was not consulted, board staff proposed rule amendments to ensure clarity.

---

RULES PROPOSED:

855-006-0005, 855-041-1001, 855-139-0005

AMEND: 855-006-0005

RULE SUMMARY: Due to COVID-19, licensees need the ability to work remotely at a secured off-site, non-pharmacy location. The amended definition of "supervision by a pharmacist" permits a Pharmacist to supervise, direct and control the work of Interns and Certified Oregon Pharmacy Technicians who are not stationed within the same work area as the Pharmacist to work remotely at a secured off-site, non-pharmacy location. The proposed rule amendments would also reorganize and relocate some definitions currently in Division 041/139 to Division 006 which will streamline definitions and make the definitions easier to locate by registrants, licensees and the public. Adds a definition for "temperature excursion."

CHANGES TO RULE:

855-006-0005  
Definitions ¶¶

As used in OAR Chapter 855:¶

(1) "Adulterated" has the same meaning as set forth in 21 USC 351 (v. 12/09/2021)¶

(2) "Alarm system" means a device or series of devices, which emit or transmit an audible or remote visual or electronic alarm signal, which is intended to summon a response.¶

(3) "Audiovisual communication system" means a continuously accessible, two-way audiovisual link that allows audiovisual communication in real-time and that prevents unauthorized disclosure of protected health information.¶

(4) "Biological product" means, with respect to the prevention, treatment or cure of a disease or condition of human beings, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component, blood derivative, allergenic product, protein other than a chemically synthesized polypeptide, analogous products or arsphenamine or any other trivalent organic arsenic compound.¶

(5) "Biosimilar" product means a biological product licensed by the United States Food and Drug Administration pursuant to 42 USC 262(k)(3)(A)(i) (12/1/2021).¶

(6) "Board" means the Oregon Board of Pharmacy unless otherwise specified or required by the context.¶

(37) "Certified Oregon Pharmacy Technician" means a person licensed by the State Board of Pharmacy who assists the pharmacist in the practice of pharmacy pursuant to rules of the board and has completed the specialized education program pursuant to OAR 855-025-0005. Persons used solely for clerical duties, such as recordkeeping, cashing, bookkeeping and delivery of medications released by the pharmacist are not considered pharmacy technicians.¶

(48) "Clinical Pharmacy Agreement" means an agreement between a pharmacist or pharmacy and a health care organization or a physician that permits the pharmacist to engage in the practice of clinical pharmacy for the benefit of the patients of the health care organization or physician.¶

(59) "Collaborative Drug Therapy Management" means the participation by a pharmacist in the management of drug therapy pursuant to a written protocol that includes information specific to the dosage, frequency, duration and route of administration of the drug, authorized by a practitioner and initiated upon a prescription order for an individual patient and:¶

(a) Is agreed to by one pharmacist and one practitioner; or¶

(b) Is agreed to by one or more pharmacists at a single pharmacy registered by the board and one or more practitioners in a single organized medical group, such as a hospital medical staff, clinic or group practice, including but not limited to organized medical groups using a pharmacy and therapeutics committee.¶

(610) "Compounding" means the preparation, mixing, assembling, packaging, or labeling of a drug or device:¶

(a) As the result of a practitioner's prescription drug order, or initiative based on the relationship between the practitioner, the pharmacist and the patient, in the course of professional practice; or¶

(b) For the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale or dispensing; or¶

(c) The preparation of drugs or devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns.¶

(711) "Confidential Information" means any patient information obtained by a pharmacist or pharmacy.¶

(812) "Consulting Pharmacist" means a pharmacist that provides a consulting service regarding a patient medication, therapy management, drug storage and management, security, education, or any other pharmaceutical service.¶

(913) The "Container" is the device that holds the drug and that is or may be in direct contact with the drug.¶

(104) "Dispensing or Dispense" means the preparation and delivery of a prescription drug pursuant to a lawful order of a practitioner in a suitable container appropriately labeled for subsequent administration to or use by a patient or other individual entitled to receive the prescription drug.¶

(145) "Entry system" enables control of access to a secured area.¶

(16) "Interchangeable" means, in reference to a biological product, that the United States Food and Drug Administration has determined that a biosimilar product meets the safety standards set forth in 42 USC 262(k)(4) (12/01/2021).¶

(17) "Interpretation and evaluation of prescription orders" means the review of the order for therapeutic and legal correctness. Therapeutic review includes identification of the prescription drug ordered, its applicability and its relationship to the other known medications used by the patient and determination of whether or not the dose and time interval of administration are within accepted limits of safety. The legal review for correctness of the prescription order includes a determination that the order is valid and has not been altered, is not a forgery, is prescribed for a legitimate medical purpose, contains all information required by federal and state law, and is within the practitioner's scope of practice.¶

(128) "Labeling" means the process of preparing and affixing of a label to any drug container exclusive, however, of the labeling by a manufacturer, packer or distributor of a non-prescription drug or commercially packaged legend

drug or device.¶

(139) "Misbranded" has the same definition as set forth in 21 USC 352 (v. 12/09/2021).¶

(1420) "Monitoring of therapeutic response or adverse effect of drug therapy" means the follow up of the therapeutic or adverse effect of medication upon a patient, including direct consultation with the patient or his agent and review of patient records, as to result and side effect, and the analysis of possible interactions with other medications that may be in the medication regimen of the patient. This section shall not be construed to prohibit monitoring by practitioners or their agents.¶

(215) "Medication Therapy Management (MTM)" means a distinct service or group of services that is intended to optimize therapeutic outcomes for individual patients. Medication Therapy Management services are independent of, but can occur in conjunction with, the provision of a medication product.¶

(1622) "Nationally Certified Exam" means an exam that is approved by the board which demonstrates successful completion of a Specialized Education Program. The exam must be reliable, psychometrically sound, legally defensible and valid.¶

(1723) "Non-legend drug" means a drug which does not require dispensing by prescription and which is not restricted to use by practitioners only.¶

(1824) "Offering or performing of those acts, services, operations or transactions necessary in the conduct, operation, management and control of pharmacy" means, among other things:¶

(a) The creation and retention of accurate and complete patient records;¶

(b) Assuming authority and responsibility for product selection of drugs and devices;¶

(c) Developing and maintaining a safe practice setting for the pharmacist, for pharmacy staff and for the general public;¶

(d) Maintaining confidentiality of patient information.¶

(1925) "Official compendium" means the official United States Pharmacopeia <USP>, official National Formulary <NF> (USP 43-NF 38 v. 2021), official Homeopathic Pharmacopoeia of the United States <HPUS> (v. 2021), or any supplement to any of these. ¶

(206) "Oral Counseling" means an oral communication process between a pharmacist and a patient or a patient's agent in which the pharmacist obtains information from the patient (or agent) and the patient's pharmacy records, assesses that information and provides the patient (or agent) with professional advice regarding the safe and effective use of the prescription drug for the purpose of assuring therapeutic appropriateness.¶

(217) Participation in Drug Selection and Drug Utilization Review:¶

(a) "Participation in drug selection" means the consultation with the practitioner in the selection of the best possible drug for a particular patient.¶

(b) "Drug utilization review" means evaluating prescription drug order in light of the information currently provided to the pharmacist by the patient or the patient's agent and in light of the information contained in the patient's record for the purpose of promoting therapeutic appropriateness by identifying potential problems and consulting with the prescriber, when appropriate. Problems subject to identification during drug utilization review include, but are not limited to:¶

(A) Over-utilization or under-utilization;¶

(B) Therapeutic duplication;¶

(C) Drug-disease contraindications;¶

(D) Drug-drug interactions;¶

(E) Incorrect drug dosage;¶

(F) Incorrect duration of treatment;¶

(G) Drug-allergy interactions; and¶

(H) Clinical drug abuse or misuse.¶

(228) "Pharmaceutical Care" means the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life. These outcomes include:¶

(a) Cure of a disease;¶

(b) Elimination or reduction of a patient's symptomatology;¶

(c) Arrest or slowing of a disease process; or¶

(d) Prevention of a disease or symptomatology.¶

(239) "Pharmacy Technician" means a person licensed by the State Board of Pharmacy who assists the pharmacist in the practice of pharmacy pursuant to rules of the board but has not completed the specialized education program pursuant to OAR 855-025-0012.¶

(2430) "Practice of clinical pharmacy" means:¶

(a) The health science discipline in which, in conjunction with the patient's other practitioners, a pharmacist provides patient care to optimize medication therapy and to promote disease prevention and the patient's health and wellness;¶

(b) The provision of patient care services, including but not limited to post-diagnostic disease state management

services; and¶

(c) The practice of pharmacy by a pharmacist pursuant to a clinical pharmacy agreement.¶

(2531) "Practice of pharmacy" is as defined in ORS 689.005.¶

(326) "Prescription drug" or "legend drug" is as defined in ORS 689.005 and:¶

(a) Required by federal law, prior to being dispensed or delivered, to be labeled with "Rx only"; or¶

(b) Required by any applicable federal or state law or regulation to be dispensed on prescription only or is restricted to use by practitioners only.¶

(2733) "Prescription released by the pharmacist" means, a prescription which has been reviewed by the pharmacist that does not require further pharmacist intervention such as reconstitution or counseling.¶

(2834) "Prohibited conduct" means conduct by a licensee that:¶

(a) Constitutes a criminal act against a patient or client; or¶

(b) Constitutes a criminal act that creates a risk of harm to a patient or client.¶

(2935) "Proper and safe storage of drugs and devices and maintenance of proper records therefore" means housing drugs and devices under conditions and circumstances that:¶

(a) Assure retention of their purity and potency;¶

(b) Avoid confusion due to similarity of appearance, packaging, labeling or for any other reason;¶

(c) Assure security and minimize the risk of their loss through accident or theft;¶

(d) Accurately account for and record their receipt, retention, dispensing, distribution or destruction;¶

(e) Protect the health, safety and welfare of the pharmacist, pharmacy staff and the general public from harmful exposure to hazardous substances.¶

(306) "Quality Assurance Plan" is a written set of procedures to ensure that a pharmacy has a planned and systematic process for the monitoring and evaluation of the quality and appropriateness of pharmacy services and for identifying and resolving problems.¶

(317) "Reference biological product" means the biological product licensed pursuant to 42 USC 262(a) (12/01/2021) against which a biological product is evaluated in an application submitted to the United States Food and Drug Administration for licensure of a biological product as a biosimilar product or for determination that a biosimilar product is interchangeable.¶

(38) "Repackage" means the act of taking a drug from the container in which it was distributed by the manufacturer and placing it into a different container without further manipulation of the drug.¶

(39) "Responsibility for advising, when necessary or when regulated, of therapeutic values, content, hazards and use of drugs and devices" means advice directly to the patient, either verbally or in writing as required by these rules or federal regulation, of the possible therapeutic response to the medication, the names of the chemicals in the medication, the possible side effects of major importance, and the methods of use or administration of a medication.¶

(3240) "Specialized Education Program" means:¶

(a) A program providing education for persons desiring licensure as pharmacy technicians that is approved by the board and offered by an accredited college or university that grants a two-year degree upon successful completion of the program; or¶

(b) A structured program approved by the board and designed to educate pharmacy technicians in one or more specific issues of patient health and safety that is offered by:¶

(A) An organization recognized by the board as representing pharmacists or pharmacy technicians;¶

(B) An employer recognized by the board as representing pharmacists or pharmacy technicians; or¶

(C) A trade association recognized by the board as representing pharmacies.¶

(341) "Still image capture" means a specific image captured electronically from a video or other image capture device.¶

(42) "Store and forward" means a video or still image record which is saved electronically for future review.¶

(43) "Supervision by a pharmacist" means being stationed within the same work area, except as authorized under OAR 855-041-3200 through OAR 855-041-3250, as the pharmacy technician or certified Oregon pharmacy technician being supervised, coupled with the ability to control and be responsible for the pharmacy technician or certified Oregon pharmacy technician's action. During the declared public health emergency timeframe related to the 2020 COVID-19 pandemic, "supervision by a pharmacist" means pharmacist monitoring of a pharmacy technician or intern being supervised, coupled with the ability to control and be responsible for the technician or interns actions and for the following remote processing functions only: prescription or order entry, other data entry, and insurance processing of prescriptions and medication orders. ¶

(344) "Surveillance system" means a system of video cameras, monitors, recorders, and other equipment used for surveillance.¶

(45) "Telepharmacy system" means a system of telecommunications technologies that enables monitoring, documenting and recording of the delivery of pharmacy services at a remote location by an electronic method which must include the use of audio and video, still image capture, and store and forward.¶

(46) "Temperature excursion" means an event in which a drug is exposed to a temperature outside of the manufacturer's required storage conditions. If the drug's manufacturer does not include required storage conditions, "temperature excursion" means an event in which a drug is exposed to a temperature outside of that required in an official compendium to ensure that the drug identity, strength, quality, and purity are not adversely affected.¶

(47) "Therapeutic substitution" means the act of dispensing a drug product with a different chemical structure for the drug product prescribed under circumstances where the prescriber has not given clear and conscious direction for substitution of the particular drug for the one which may later be ordered.¶

(3548) "Verification" means the confirmation by the pharmacist of the correctness, exactness, accuracy and completeness of the acts, tasks, or functions performed by an intern or a pharmacy technician or a certified Oregon pharmacy technician.

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.151, ORS 689.155

AMEND: 855-041-1001

RULE SUMMARY: The proposed amendments relocate some definitions in Division 041 to Division 006 which will streamline definitions and make the definitions easier to locate by registrants, licensees and the public.

CHANGES TO RULE:

855-041-1001

Definitions ¶¶

~~(1) "Biological product" means, with respect to the prevention, treatment or cure of a disease or condition of human beings, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component, blood derivative, allergenic product, protein other than a chemically synthesized polypeptide, analogous products or arsphenamine or any other trivalent organic arsenic compound.¶¶~~

~~(2) "Biosimilar" product means a biological product licensed by the United States Food and Drug Administration pursuant to 42 USC 262(k)(3)(A)(i) (12/1/2021).¶¶~~

~~(3) "Drug room" is a drug storage area registered with the board which is secure and lockable.¶¶~~

~~(4) "Interchangeable" means, in reference to a biological product, that the United States Food and Drug Administration has determined that a biosimilar product meets the safety standards set forth in 42 USC 262(k)(4) (12/01/2021).¶¶~~

~~(5) "Reference biological product" means the biological product licensed pursuant to 42 USC 262(a) (12/01/2021) against which a biological product is evaluated in an application submitted to the United States Food and Drug Administration for licensure of a biological product as a biosimilar product or for determination that a biosimilar product is interchangeable.¶¶~~

~~(6) "Repackage" means the act of taking a drug from the container in which it was distributed by the manufacturer and placing it into a different container without further manipulation of the drug."Drug room" is a drug storage area registered with the board which is secure and lockable.~~

Statutory/Other Authority: ORS 689.205, ORS 689.522

Statutes/Other Implemented: ORS 689.155, ORS 689.522

RULE SUMMARY: The proposed rule amendments relocate some definitions in Division 139 to Division 006 which will streamline definitions and make the definitions easier to locate by registrants, licensees and the public.

CHANGES TO RULE:

855-139-0005

Definitions

The following words and terms, when used in OAR 855-139, have the following meanings, unless the context clearly indicates otherwise. Any term not defined in this section has the definition set out in OAR 855-006.

- (1) "Biological product" means, with respect to the prevention, treatment or cure of a disease or condition of human beings, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component, blood derivative, allergenic product, protein other than a chemically synthesized polypeptide, analogous products or arsphenamine or any other trivalent organic arsenic compound.
  - (2) "Biosimilar product" means a biological product licensed by the United States Food and Drug Administration pursuant to 42 USC 262(k)(3)(A)(i) (12/01/2021).
  - (3) "Interchangeable" means, in reference to a biological product, that the United States Food and Drug Administration has determined that a biosimilar product meets the safety standards set forth in 42 USC 262(k)(4) (12/01/2021).
  - (4) "RDSP Affiliated Pharmacy" means a Retail Drug Outlet Pharmacy registered in Oregon where an Oregon licensed Pharmacist provides pharmacy services through a telepharmacy system.
  - (5) "Reference biological product" means the biological product licensed pursuant to 42 USC 262(a) (12/01/2021) against which a biological product is evaluated in an application submitted to the United States Food and Drug Administration for licensure of a biological product as a biosimilar product or for determination that a biosimilar product is interchangeable.
  - (6) "Remote Dispensing Site Pharmacy" or "RDSP" means an Oregon location registered as a Retail Drug Outlet Remote Dispensing Site Pharmacy staffed by a Certified Oregon Pharmacy Technician under the supervision, direction and control of an Oregon licensed Pharmacist using a telepharmacy system.
  - (7) "Repackage" means the act of taking a drug from the container in which it was distributed by the manufacturer and placing it into a different container without further manipulation of the drug.
  - (8) "Still image capture" means a specific image captured electronically from a video or other image capture device.
  - (9) "Store and forward" means a video or still image record which is saved electronically for future review.
  - (10) "Telepharmacy" means the delivery of pharmacy services by an Oregon licensed Pharmacist through the use of a telepharmacy system to a patient at a remote location staffed by a Certified Oregon Pharmacy Technician.
  - (11) "Telepharmacy system" means a system of telecommunications technologies that enables monitoring, documenting and recording of the delivery of pharmacy services at a remote location by an electronic method which must include the use of audio and video, still image capture, and store and forward.
- RDSP Affiliated Pharmacy" means a Retail Drug Outlet Pharmacy registered in Oregon where an Oregon licensed Pharmacist provides pharmacy services through a telepharmacy system.
- (2) "Remote Dispensing Site Pharmacy" or "RDSP" means an Oregon location registered as a Retail Drug Outlet Remote Dispensing Site Pharmacy staffed by a Certified Oregon Pharmacy Technician under the supervision, direction and control of an Oregon licensed Pharmacist using a telepharmacy system.
- (3) "Telepharmacy" means the delivery of pharmacy services by an Oregon licensed Pharmacist through the use of a telepharmacy system to a patient at a remote location staffed by a Certified Oregon Pharmacy Technician.

Statutory/Other Authority: ORS 689.205, ORS 689.522, 2021 SB 629

Statutes/Other Implemented: ORS 689.522, ORS 689.564, 2021 SB 629